Drug Trial Radar · NCT04057898
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
234
Actual
Start
May 28, 2020
Primary completion
Apr 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- MediciNovaIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
MN-166Drug
Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
placeboDrug
Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.Time frame: 12 months
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
University of California
Orange, California
Mayo Clinic
Jacksonville, Florida
Augusta University
Augusta, Georgia
Indiana University IU Health Neuroscience Center
Indianapolis, Indiana
Johns Hopkins University
Baltimore, Maryland
Hennepin Healthcare Research Institute
Minneapolis, Minnesota
SUNY Upstate Medical University
Syracuse, New York
Duke University
Durham, North Carolina
Lehigh Valley Health Network
Allentown, Pennsylvania
University of Virginia Health System
Charlottesville, Virginia
Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval
Québec, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
McMaster University Medical Center
Hamilton, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
University of Saskatchewan - Sastakoon Hospital
Saskatoon, Saskatchwean, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.